Bart Bortz, of Sun Prairie, Wis., defied the odds in his battle against cancer, thanks to groundbreaking research and treatment at UW Health’s Carbone Cancer Center....
UW Health has again received the LGBTQ+ Healthcare Equality Leader designation from the Human Rights Campaign Foundation....
Dorota A. Grejner-Brzezinska will serve as the University of Wisconsin–Madison’s vice chancellor for research. Chancellor Jennifer L. Mnookin named Brzezinska, a longtime Ohio State University engineering professor and GPS researcher, to the post today....
Innovation does not happen in a vacuum—the biggest breakthroughs in cancer treatment and prevention happen because of teamwork across disciplines and between multiple academic centers and research institutions....
In an effort to improve delivery of costly medical treatments, a team of researchers in electrical engineering at the University of Wisconsin–Madison has developed a stimulating method that could make the human body more receptive to certain gene therapies....
Pregnant people have the same diseases as others, including depression, diabetes, high blood pressure, cancer, and HIV. And pregnancy can cause serious conditions that require the use of medicine....
As one dives into the annals of cancer research history, the astounding pace of drug discovery and development, coupled with the emergence of multimodal and multidisciplinary innovations, evokes a sense of wonder....
Due to requirements for compliance, data gathering and monitoring, beginning July 1, 2024, all clinical research that is conducted by SMPH faculty or uses UW Health patients or resources is required to be entered into OnCore....
If “recruiting and screening patients who try new treatments and monitoring and reporting on patient progress” sounds like a reasonable, if skimpy, definition of the duties of a clinical research coordinator (CRC) at a clinical trial site, imagine the surprise of a newly minted CRC...
Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer....
